Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP4 | P27487 | 1/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 2/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | JAK2 | O60674 | 1/20 | 0.41 |
| ▸ | JAK1 | P23458 | 1/20 | 0.41 |
| ▸ | TACR1 | P25103 | 1/20 | 0.41 |
| ▸ | TNKS | O95271 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.40 |
| ▸ | TNKS2 | Q9H2K2 | 1/20 | 0.40 |
| ▸ | RORC | P51449 | 1/20 | 0.40 |
| ▸ | GPR4 | P46093 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22265768 | 0.87 | TACR1 (0.43) | DPP4GPR119HDAC2HDAC1JAK2 | |
| SCHEMBL26081098 | 0.87 | GPR119 (0.44) | DPP4GPR119HDAC2HDAC1JAK2 | |
| SCHEMBL14841042 | 0.85 | DPP4 (0.47) | DPP4GPR119HDAC2HDAC1TACR1 | |
| SCHEMBL22719370 | 0.83 | JAK2 (0.45) | DPP4GPR119HDAC2HDAC1JAK2 | |
| SCHEMBL25389347 | 0.83 | GPR119 (0.52) | DPP4GPR119HDAC2HDAC1JAK2 | |
| SCHEMBL5672765 | 0.82 | KDM1A (0.48) | GPR119HDAC2HDAC1JAK2JAK1 | |
| SCHEMBL14840951 | 0.81 | DPP4 (0.46) | DPP4GPR119JAK2JAK1TACR1 | |
| SCHEMBL8111848 | 0.81 | GPR119 (0.52) | GPR119HDAC2HDAC1TACR1 | |
| SCHEMBL24408921 | 0.80 | GPR119 (0.51) | DPP4GPR119JAK2JAK1 | |
| SCHEMBL8116325 | 0.80 | GPR119 (0.51) | DPP4GPR119TACR1RORCSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | SAGE THERAPEUTICS, INC. | 2023-10-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230312522-A1 | CYP46A1 INHIBITORS AND METHODS OF USE THEREOF | CYP46A1, CYP26A1, CYP4A22 | DPP4 1247/4885GPR119 721/4885HDAC2 1401/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.